At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

In addition to his positions at Prometheus and Abbvie, Mr. Stenhouse held an executive leadership ... enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with ...

David Risinger’s rating is based on several key considerations surrounding AbbVie’s recent clinical trial outcomes. The company’s announcement on November 11, 2024, revealed that emraclidine’s Phase 2 ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

"AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials" was originally created and published by ...

JS and TV are supported by a senior clinical researcher fellowship from the Research Foundation Flanders (FWO). Competing ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Key Takeaways Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in ...